Aptar’s nasal vaccine device is now CE marked. Could it help bring more needle-free vaccines to market?
Aptar Pharma has obtained European CE marking for LuerVax and its optional Spray Divider, establishing a medical device compliance framework for intranasal vaccine administration. The milestone builds on clinical development use of the platform but does not constitute approval of any vaccine delivered through it.